p53相关蛋白激酶介导多发性骨髓瘤不良预后并代表新型治疗靶点
研究发现p53相关蛋白激酶(TP53RK/PRPK)在多发性骨髓瘤(MM)中与不良预后相关,敲低TP53RK可抑制p53磷酸化并诱导MM细胞凋亡,且免疫调节药物(IMiDs)可结合并抑制TP53RK,提示TP53RK为不良预后MM患者的新型治疗靶点。
要点
- TP53RK高表达与MM患者不良预后相关,敲低TP53RK可诱导MM细胞凋亡。
- IMiDs可结合并抑制TP53RK,产生与TP53RK敲低相似的生物学效应。
- 遗传或药理抑制TP53RK通过p53-Myc轴依赖和非依赖途径触发MM细胞凋亡。
核心结论
- 遗传或药理抑制TP53RK通过p53-Myc轴依赖和非依赖途径触发MM细胞凋亡,验证TP53RK为不良预后MM患者的新型治疗靶点。
研究设计与样本
- 研究采用多种实验方法,包括基因敲低、pull-down、核磁共振波谱、差示扫描荧光法和等温滴定量热法,检测TP53RK在MM细胞中的作用及IMiDs与TP53RK的结合。
主要发现
- TP53RK敲低抑制p53磷酸化并触发MM细胞凋亡,伴随c-Myc下调和E2F-1介导的促凋亡蛋白Bim上调。
- TP53RK下调在p53缺陷和p53突变MM细胞系中也可触发生长抑制。
- 鉴定出TP53RK下游新靶点包括核糖核苷酸还原酶-1、端粒酶逆转录酶和周期蛋白依赖性激酶抑制剂2C。
- IMiDs结合并抑制TP53RK,产生与TP53RK敲低相似的生物学效应。
关键数值与推荐
- TP53RK磷酸化p53的丝氨酸残基Ser15并介导p53活性。
- IMiDs通过pull-down、核磁共振波谱、差示扫描荧光法和等温滴定量热法证实与TP53RK结合并抑制其活性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
p53-related protein kinase (TP53RK, also known as PRPK) is an upstream kinase that phosphorylates (serine residue Ser15) and mediates p53 activity. Here we show that TP53RK confers poor prognosis in multiple myeloma (MM) patients, and, conversely, that TP53RK knockdown inhibits p53 phosphorylation and triggers MM cell apoptosis, associated with downregulation of c-Myc and E2F-1-mediated upregulation of pro-apoptotic Bim. We further demonstrate that TP53RK downregulation also triggers growth inhibition in p53-deficient and p53-mutant MM cell lines and identify novel downstream targets of TP53RK including ribonucleotide reductase-1, telomerase reverse transcriptase, and cyclin-dependent kinase inhibitor 2C. Our previous studies showed that immunomodulatory drugs (IMiDs) downregulate p21 and trigger apoptosis in wild-type-p53 MM.1S cells, Importantly, we demonstrate by pull-down, nuclear magnetic resonance spectroscopy, differential scanning fluorimetry, and isothermal titration calorimetry that IMiDs bind and inhibit TP53RK, with biologic sequelae similar to TP53RK knockdown. Our studies therefore demonstrate that either genetic or pharmacological inhibition of TP53RK triggers MM cell apoptosis via both p53-Myc axis-dependent and axis-independent pathways, validating TP53RK as a novel therapeutic target in patients with poor-prognosis MM.
引用
- Hideshima T, Cottini F, Nozawa Y, et al. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017. PMID: 28082445. doi:10.1182/blood-2016-09-738500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。